JY
DNTH icon

Jeff Yass’s Dianthus Therapeutics DNTH Stock Holding History

Jeff Yass’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Sell
30,237
-49,764
-62% -$4.35M ﹤0.01% 5664
2026
Q1 		$6.71M Buy
80,001
+28,535
+55% +$1.65M ﹤0.01% 3738
2025
Q4 		$2.12M Buy
51,466
+39,405
+327% +$1.53M ﹤0.01% 5543
2025
Q3 		$475K Sell
12,061
-18,006
-60% -$460K ﹤0.01% 9081
2025
Q2 		$560K Sell
30,067
-17,311
-37% -$325K ﹤0.01% 8903
2025
Q1 		$859K Buy
47,378
+30,856
+187% +$680K ﹤0.01% 7637
2024
Q4 		$360K Buy
+16,522
New +$425K ﹤0.01% 9418
2024
Q2 		– Sell
-205,487
Closed -$6.16M – 12248
2024
Q1 		$6.16M Buy
205,487
+176,808
+617% +$3.84M ﹤0.01% 3301
2023
Q4 		$298K Buy
+28,679
New +$317K ﹤0.01% 9856
2023
Q3 		– Sell
-6,456
Closed -$78.3K – 12183
2023
Q2 		$78.3K Sell
6,456
-4,888
-43% -$55.6K ﹤0.01% 11115
2023
Q1 		$144K Buy
+11,344
New +$126K ﹤0.01% 10950
2022
Q3 		– Sell
-2,873
Closed -$55K – 13343
2022
Q2 		$55K Buy
+2,873
New +$71K ﹤0.01% 11926
2022
Q1 		– Sell
-652
Closed -$46K – 13155
2021
Q4 		$46K Buy
+652
New +$65.5K ﹤0.01% 12586
2021
Q3 		– Sell
-1,288
Closed -$201K – 12871
2021
Q2 		$201K Sell
1,288
-397
-24% -$72.9K ﹤0.01% 11589
2021
Q1 		$319K Buy
1,685
+775
+85% +$130K ﹤0.01% 10479
2020
Q4 		$114K Sell
910
-289
-24% -$32.8K ﹤0.01% 10432
2020
Q3 		$130K Buy
+1,199
New +$142K ﹤0.01% 9780
2019
Q4 		– Sell
-664
Closed -$109K – 9863
2019
Q3 		$109K Buy
+664
New +$126K ﹤0.01% 9521

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Jeff Yass's DNTH Position: Q2 2026 in Review

Jeff Yass reduced its Dianthus Therapeutics (DNTH) stake by 62% in Q2 2026, selling an estimated $4.35M and leaving 30,237 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #5664.

Jeff Yass first reported a position in DNTH in Q3 2019 and has held it in 18 quarters since. The position peaked at $6.71M in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Jeff Yass held 30,237 shares of Dianthus Therapeutics worth $2.95M as of Q2 2026.
  • Jeff Yass sold 49,764 Dianthus Therapeutics shares in Q2 2026, an estimated $4.35M.
  • Dianthus Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5664 holding.
  • Jeff Yass first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Jeff Yass's Dianthus Therapeutics position peaked at $6.71M in Q1 2026.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.